Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in LGS therapeutics.

More than 89,000 total prevalent cases of LGS are anticipated in 2023 in the 16 countries covered in the analyst’s epidemiology forecast for LGS.

All of the marketed products for LGS are small molecules and are mainly receptor agonists or ion channel blockers.

Out of 30 drugs in development for LGS, one is in pre-registration and three are in Phase III.

Commercial sponsors have led the clinical trials space for LGS over the past 10 years, with Takeda Pharmaceutical sponsoring the highest number of trials overall (15 trials).

In deals involving companies developing LGS assets, acquisition was the most prevalent deal type in Asia Pacific, Africa, and Europe, while partnership took the major chunk of share across African and European markets.

Scope

The analyst's LGS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the LGS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global LGS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.